A new antibiotic and bacterial diagnostic platform, known as the MicroPhage MRSA/MSSA Blood Culture Test, has been developed in the US to test samples in just five hours or less compared with up to three days for other tests.

The test detects Staphylococcus aureus (“staph”) bacteria and verifies methicillin resistance (MRSA) or susceptibility (MSSA) in a patient suspected with bloodstream infections.

Tests currently used to diagnose these types of infections take up to three days for results, which can lead to ineffectual treatment and death.

The test contains two small reaction tubes for incubating blood culture specimens, which deliver results in five hours, allowing physicians to determine more effective and precise antibiotics that could shorten hospital stays, lower rising healthcare costs and save lives.

The product has received CE Mark approval and is awaiting review from the US Food and Drug Administration (FDA).